SecBot SecBot

RAPT

RAPT Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001673772 Biotech & Drug Discovery
No price
Median target
$58.00
range $58.00–58.00
Insider net
$0
no open-market trades · since Mar 3
New fund stakes
0
Q1 2026 13F · 3 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Mar 3. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q1 2026: 0 added (0 new), 3 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.762 → −$1.027 over 90 days.

Who's buying

13F· Q1 2026
0
new positions
3
exits
FundMoveSharesValue
STATE STREET CORPEXIT0$0.00
RTW INVESTMENTS, LPEXIT0$0.00
BlackRock, Inc.EXIT0$0.00
VANGUARD GROUP INCADD1,186,791$40.2M
STATE STREET CORPDOUBLED639,804$21.7M
BlackRock, Inc.DOUBLED486,153$16.5M
GOLDMAN SACHS GROUP INCDOUBLED254,053$8.6M
GEODE CAPITAL MANAGEMENT, LLCADD239,790$8.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jan 2026
Recent actions
DateFirmActionRating
Jan 21, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Jan 21, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Jan 20, 2026Wells Fargo
DOWNGRADE
DOWNGRADEEqual-Weight
Jan 20, 2026LifeSci Capital
DOWNGRADE
DOWNGRADEMarket Perform
Jan 20, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Jan 20, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
open-market buys or sells · since Mar 3
DateInsiderTypeValue
Mar 3, 2026
Lyons-Williams Lori
Director
Mar 3, 2026
TO ISSUER2,813 sh
Mar 3, 2026
GRAY MARY ANN
Director
Mar 3, 2026
TO ISSUER1,072 sh
Mar 3, 2026
GRAY MARY ANN
Director
Mar 3, 2026
TO ISSUER1,618 sh
Mar 3, 2026
Brockstedt Dirk G.
CHIEF SCIENTIFIC OFFICER
Mar 3, 2026
TO ISSUER6,250 sh
Mar 3, 2026
Giordano Michael F
Director
Mar 3, 2026
TO ISSUER4,561 sh
Mar 3, 2026
Giordano Michael F
Director
Mar 3, 2026
TO ISSUER1,063 sh
Mar 3, 2026
Braunstein Scott
Director
Mar 3, 2026
TO ISSUER25,000 sh
Mar 3, 2026
Brockstedt Dirk G.
CHIEF SCIENTIFIC OFFICER
Mar 3, 2026
TENDER4,648 sh

Earnings setup

Estimates
−$1.03
EPS estimate, this quarter
−35%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Next Q-$0.57-$0.72–-$0.43+12.5%$0.00
Current Q-$1.03-$1.30–-$0.83-16.2%$0.00
Current FY-$2.83-$2.95–-$2.74-14.3%$0.00
Next FY-$2.71-$3.26–-$1.77+12.6%$0.00
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Aug 5, 2026 Earnings calendar
RAPT Q2 2026 Earnings Scheduled, 2026-08-05
Mar 31, 2026 Inst.
STATE STREET CORP · EXIT
0 shares ($0.00)
Mar 31, 2026 Inst.
RTW INVESTMENTS, LP · EXIT
0 shares ($0.00)
Mar 18, 2026 SEC
RAPT Therapeutics has filed Form 15 to terminate its SEC registration and suspend reporting obligations following its…
15-12G · Impact 7/10
Mar 3, 2026 Insider
Lyons-Williams Lori disposed of 2,813 shares
Director
Mar 3, 2026 Insider
GRAY MARY ANN disposed of 1,072 shares
Director
Mar 3, 2026 Insider
GRAY MARY ANN disposed of 1,618 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

1 filing · 0 bullish · 0 bearish · 1 neutral
All RAPT filing & press-release reports (1)